CA2094974A1 - Stable porfimer sodium compositions and methods for their manufacture - Google Patents

Stable porfimer sodium compositions and methods for their manufacture

Info

Publication number
CA2094974A1
CA2094974A1 CA2094974A CA2094974A CA2094974A1 CA 2094974 A1 CA2094974 A1 CA 2094974A1 CA 2094974 A CA2094974 A CA 2094974A CA 2094974 A CA2094974 A CA 2094974A CA 2094974 A1 CA2094974 A1 CA 2094974A1
Authority
CA
Canada
Prior art keywords
composition
porfimer sodium
stable
manufacture
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2094974A
Other languages
French (fr)
Other versions
CA2094974C (en
Inventor
Steven L. Clauss
Michael J. Pastel
Rainer K. Zawadzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptalis Pharma Canada ULC
Original Assignee
Quadra Logic Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Technologies Inc filed Critical Quadra Logic Technologies Inc
Publication of CA2094974A1 publication Critical patent/CA2094974A1/en
Application granted granted Critical
Publication of CA2094974C publication Critical patent/CA2094974C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A storage stable porfimer sodium (polyhematoporphyrin ether/ester) composition useful in the photodynamic therapy of cancer and other conditions is provided. The composition is characterized in that the percentage of ester linked porphyrin oligomers is less than 10% of the composition. Improved processes for preparing such compositions are also provided wherein acetylated hematoporphyrin is treated with alkali for sufficient time and temperature to reduce the amount of porphyrin oligomers joined by ester linkages to less than 10% of the composition.
CA002094974A 1992-04-27 1993-04-27 Stable porfimer sodium compositions and methods for their manufacture Expired - Lifetime CA2094974C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US873,860 1992-04-27
US07/873,860 US5244914A (en) 1992-04-27 1992-04-27 Stable porfimer sodium compositions and methods for their manufacture

Publications (2)

Publication Number Publication Date
CA2094974A1 true CA2094974A1 (en) 1993-10-28
CA2094974C CA2094974C (en) 1996-10-22

Family

ID=25362473

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002094974A Expired - Lifetime CA2094974C (en) 1992-04-27 1993-04-27 Stable porfimer sodium compositions and methods for their manufacture

Country Status (10)

Country Link
US (2) US5244914A (en)
EP (1) EP0568323B1 (en)
JP (1) JP2928047B2 (en)
KR (1) KR100221206B1 (en)
AT (1) ATE150968T1 (en)
CA (1) CA2094974C (en)
DE (1) DE69309340T2 (en)
DK (1) DK0568323T3 (en)
ES (1) ES2104056T3 (en)
GR (1) GR3023978T3 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5371199B1 (en) * 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US7097826B2 (en) * 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7078014B2 (en) * 1999-12-23 2006-07-18 Health Research, Inc. Method for using chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US6534040B2 (en) 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
BRPI0506983A (en) 2004-01-20 2007-07-03 Allergan Inc localized eye therapy compositions, preferably comprising triamcinolone acetonide and hyaluronic acid
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20060052286A1 (en) * 2004-08-13 2006-03-09 Yale University Factor VII conjugates for selectively treating neovascularization disorders
US20060223750A1 (en) * 2005-04-01 2006-10-05 Allergan, Inc. Agents and methods for enhancing photodynamic therapy
JPWO2007142132A1 (en) * 2006-06-02 2009-10-22 財団法人浜松科学技術研究振興会 Novel process for producing polyvalent metal compounds of porphyrin (Y)
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US8798932B2 (en) 2008-10-31 2014-08-05 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8545855B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8545856B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8603494B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8485861B2 (en) 2008-10-31 2013-07-16 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8545857B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8221480B2 (en) 2008-10-31 2012-07-17 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8551505B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EP2498783B1 (en) 2009-11-09 2018-08-22 Allergan, Inc. Compositions and methods for stimulating hair growth
US9371555B2 (en) 2012-06-01 2016-06-21 Concordia Laboratories Inc. Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin
CA2901280A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
AU2018235945A1 (en) 2017-03-14 2019-10-17 Ohio State Innovation Foundation Methods and compositions related to a tissue factor-targeting IgG3 immunoconjugates
KR102182630B1 (en) * 2019-12-19 2020-11-24 김진왕 Eco-friendly smart photosensitizers and photobiomodulation of stem cell therapy agent using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4882234A (en) * 1986-11-12 1989-11-21 Healux, Inc. Storage-stable porphin compositions and a method for their manufacture
US4861876A (en) * 1986-11-26 1989-08-29 Wayne State University Hematoporphyrin derivative and method of preparation and purification
US5059619A (en) * 1989-06-14 1991-10-22 Quadra Logic Technologies, Inc. Stable freeze-dried polyhematoporphyrin ether/ester

Also Published As

Publication number Publication date
CA2094974C (en) 1996-10-22
JP2928047B2 (en) 1999-07-28
KR100221206B1 (en) 1999-10-01
DK0568323T3 (en) 1997-07-07
DE69309340D1 (en) 1997-05-07
US5438071A (en) 1995-08-01
EP0568323A1 (en) 1993-11-03
US5244914A (en) 1993-09-14
GR3023978T3 (en) 1997-10-31
JPH06220062A (en) 1994-08-09
KR930021143A (en) 1993-11-22
EP0568323B1 (en) 1997-04-02
DE69309340T2 (en) 1997-07-17
ES2104056T3 (en) 1997-10-01
ATE150968T1 (en) 1997-04-15

Similar Documents

Publication Publication Date Title
CA2094974A1 (en) Stable porfimer sodium compositions and methods for their manufacture
AU8458891A (en) A process for the preparation of carnosic acid and the use of the acid for its anticarcinogenic and antiviral properties
CA2027449A1 (en) Strontium nitrate containing primer composition
CA2027596A1 (en) Compositions containing hyaluronic acid complexes with zinc or cobalt
CA2054189A1 (en) Stable ascorbic acid compositions
CA2148795A1 (en) Compositions of oak bark extract, related synthetic compositions, and method of using same
AU2978797A (en) Drug complex
HK1003137A1 (en) New pyrazine derivatives their preparation and their use
AU4799885A (en) Compositions of copper and fatty acids
ZA823248B (en) New anti-thromboticum based on polysacharides,method for its preparation and pharmaceutical compositions
HU903850D0 (en) Process for producing stable dried by freezing out poly-hematoporphyrinether/esther composition
AU5428586A (en) Pharmaceutical and dietary compositions
AU669946B2 (en) Lanolin/lanolin acid ester skin treatment composition
DE3573268D1 (en) Unsaturated polyesters
CA2128103A1 (en) Formulation and use of carotenoids in treatment of cancer
ES2009248A6 (en) Dietary composition
IE39239L (en) Cycloalkyl-alkyl esters.
DE3473826D1 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
Tishchenko et al. IR spectra and structure of biologically active carbulose preparation
CA2176603A1 (en) Novel palladium complexes and methods for using same in the treatment of tumors and psoriasis
JPS54132600A (en) Preparation of pectic acid alkali metal salt
JPS55157565A (en) Fungicide

Legal Events

Date Code Title Description
EEER Examination request